Jun. 29 at 11:46 AM
$GNPX Exactly mate. At this stage patents, conferences and the same presentations are not enough anymore.
The pipeline might still have value, but the market wants something real now. Proper clinical data, Acclaim updates, a partnership, licensing deal, non dilutive funding, or anything that shows management can actually create shareholder value.
That’s the difference between just staying alive and getting a proper re rate.
Holders are tired of positive sounding PRs while the share price keeps getting destroyed.
